Physician profile
Suzanne D Quinter
NPI 1376717967
$528.47
in general payments reported to CMS, 2019-2025
10 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.85 · 2020: $113 · 2021: $43.74 · 2022: $13.71 · 2023: $172 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $172 · Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $171.99 |
| Food and Beverage | $170.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $171.99 | 2020-2023 | |
| Janssen Biotech, INC. | $127.95 | 2023-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $56.19 | 2025 | |
| Novartis Pharmaceuticals Corporation | $37.89 | 2020-2025 | |
| Genzyme Corporation | $36.17 | 2019-2025 | |
| Midmark Corporation | $27.59 | 2021 | |
| Ucb, INC. | $24.19 | 2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.64 | 2025 | Cabtreo |
| Allergan, INC. | $16.15 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Quinter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.